H
Hangzhou Chengtian Technology Development
RoboCT is dedicated to providing the disabled, the elderly and medical Rehabilitation institutes with intelligent rehabilitation devices
About Hangzhou Chengtian Technology Development
Hangzhou Chengtian Technology Development Co., Ltd., operating as RoboCT, is a technology-driven enterprise focused on the development and application of exoskeleton robotics. Founded in Hangzhou in January 2017, the company has roots in its predecessor, Harbin RoboCT Technology Development Co., Ltd., which was established in 2012. The founder and CEO, Dr. Wang Tian, has guided the company's technical evolution, drawing on his academic journey from undergraduate to doctorate studies in the robotics field. RoboCT established its headquarters in Hangzhou, a city recognized as a burgeoning hub for technology and innovation in China.
The company's core business revolves around creating exoskeleton technology, robot core components, and intelligent control systems. RoboCT primarily serves the medical rehabilitation and elderly care markets, providing intelligent devices and solutions to medical institutions and individual users. Its client base includes over 200 hospitals in China. The business model incorporates a "Rehabilitation as a Service" (RaaS) approach, which facilitates the integration of their systems into hospitals, communities, and homes through joint operations. This model, supported by a digital rehabilitation cloud platform, aims to make the rehabilitation process more accessible and efficient.
RoboCT's product portfolio includes lower limb exoskeleton robots like the UGO and KidGo models, designed for patients with motor dysfunction due to conditions such as spinal cord injuries, strokes, and cerebral palsy. These products are based on the principle of neuroplasticity, using multiple sensors and motors to provide safe and effective walking training. The UGO exoskeleton, for instance, uses intention detection and multi-sensor fusion technology to respond to user movements. The company also develops core robotic components like mecanum wheels, mobile robot platforms, and high-torque motors, which are sold to over 30 countries. Recently, RoboCT launched a consumer-grade, battery-free exoskeleton called EasyGo, designed to reduce walking fatigue, which saw immediate market uptake.
Financially, RoboCT has secured significant investment to fuel its growth. The company completed a Pre-A funding round in 2018. In April 2022, it announced a Series A+ funding round of over $15.7 million (RMB 100 million), led by Fortune Capital with participation from investors like Blue Run Ventures China, Essence Securities, and Poly Capital. These funds are intended for global expansion and to enhance commercialization capabilities. The company has achieved notable milestones, including being the first in China to receive the National Medical Products Administration (NMPA) registration certificate for a lower-limb exoskeleton robot for central neuropathy and obtaining numerous intellectual property rights and industry awards.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2026 | $14M | $55M | Hangzhou Capital · ABC Capital | ↗ |
| SERIES B✓Equity / VC | Mar 2025 | $14M | $55M | Guolian Group | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Chengtian Technology Development is 14K monthly website visits, up 191.7% over the last three months. Hangzhou Chengtian Technology Development's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Chengtian Technology Development in the Hangzhou ecosystem
The Hangzhou Chengtian Technology Development office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Fortune Venture
BlueRun Ventures- PCPoly Capital
- ESEssence Securities
- YGYuhang Guotou
Pappas Capital- GGGuolian Group
- ACABC Capital
Hangzhou Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Chengtian Technology Development on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Chengtian Technology Development’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









